CA2953682A1 - Compositions and methods for visualization of the vitreous - Google Patents

Compositions and methods for visualization of the vitreous Download PDF

Info

Publication number
CA2953682A1
CA2953682A1 CA2953682A CA2953682A CA2953682A1 CA 2953682 A1 CA2953682 A1 CA 2953682A1 CA 2953682 A CA2953682 A CA 2953682A CA 2953682 A CA2953682 A CA 2953682A CA 2953682 A1 CA2953682 A1 CA 2953682A1
Authority
CA
Canada
Prior art keywords
seq
composition
vitreous
agent
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2953682A
Other languages
English (en)
French (fr)
Inventor
Joy Ghosh
Thaddeus Peter Dryja
Michael Roguska
Eric Carlson
Original Assignee
Novartis AG
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, Alcon Inc filed Critical Novartis AG
Publication of CA2953682A1 publication Critical patent/CA2953682A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
CA2953682A 2014-06-25 2015-06-24 Compositions and methods for visualization of the vitreous Abandoned CA2953682A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462016731P 2014-06-25 2014-06-25
US62/016,731 2014-06-25
PCT/IB2015/054747 WO2015198245A1 (en) 2014-06-25 2015-06-24 Compositions and methods for visualization of the vitreous

Publications (1)

Publication Number Publication Date
CA2953682A1 true CA2953682A1 (en) 2015-12-30

Family

ID=53539753

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2953682A Abandoned CA2953682A1 (en) 2014-06-25 2015-06-24 Compositions and methods for visualization of the vitreous

Country Status (8)

Country Link
US (1) US10537648B2 (https=)
EP (1) EP3160512B1 (https=)
JP (2) JP6296581B2 (https=)
CN (1) CN107206107A (https=)
AU (1) AU2015278744B2 (https=)
CA (1) CA2953682A1 (https=)
ES (1) ES2730398T3 (https=)
WO (1) WO2015198245A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242919A1 (en) * 2024-05-24 2025-11-27 Navigo Proteins Gmbh Novel binding proteins for hyaluronic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733744A1 (en) 2005-06-17 2006-12-20 Ludwig-Maximilians-Universität München Method, dye and medicament for staining the internal limiting membrane and/or the capsule of an eye
JP4936508B2 (ja) * 2006-01-23 2012-05-23 独立行政法人国立国際医療研究センター 蛍光ナノ粒子を含む眼の硝子体染色剤及び染色方法
HUE026001T2 (en) * 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US20110236310A1 (en) 2008-12-25 2011-09-29 Canon Kabushiki Kaisha Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
WO2012135432A2 (en) 2011-03-29 2012-10-04 Kemin Industries, Inc. Dyes for membranes and biological structures
JP6162707B2 (ja) * 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
EP3838293A1 (en) * 2012-07-11 2021-06-23 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
GB201400994D0 (en) * 2014-01-21 2014-03-05 Ucl Business Plc Drug delivery system

Also Published As

Publication number Publication date
US20170202981A1 (en) 2017-07-20
US10537648B2 (en) 2020-01-21
WO2015198245A1 (en) 2015-12-30
JP2017524679A (ja) 2017-08-31
EP3160512A1 (en) 2017-05-03
ES2730398T3 (es) 2019-11-11
CN107206107A (zh) 2017-09-26
AU2015278744A1 (en) 2017-01-12
JP2018039847A (ja) 2018-03-15
JP6296581B2 (ja) 2018-03-20
EP3160512B1 (en) 2019-05-22
AU2015278744B2 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
Farah et al. The use of vital dyes during vitreoretinal surgery-chromovitrectomy
Sreekumar et al. Intra-vitreal αB crystallin fused to elastin-like polypeptide provides neuroprotection in a mouse model of age-related macular degeneration
Fernández-Colino et al. Self-assembling elastin-like hydrogels for timolol delivery: development of an ophthalmic formulation against glaucoma
US12440443B2 (en) Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver
RU2561585C2 (ru) Местный глазной пептидный состав
ES2324485T5 (es) Composición colorante para colorear una membrana oftálmica
TW201836646A (zh) 治療與血管生成及血管新生相關病症的方法
CA3095073A1 (en) Sap and peptidomimetics for treatment of eye disease
Cai et al. Injectable self-assembling peptide hydrogel as a promising vitreous substitute
Xu et al. Thermoresponsive gel for sustained release of BMP4 to inhibit corneal neovascularization
US10537648B2 (en) Compositions and methods for visualization of the vitreous
Yamamoto et al. Visualizing vitreous using quantum dots as imaging agents
CN109640973A (zh) 近视的治疗
US11160881B2 (en) Dendrimer compositions for use in angiography
Sarkar et al. Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies
ES2319759T5 (es) Uso de un agente colorante para la coloración de la cápsula del cristalino o de membranas formadas en la retina del ojo
Junnuthula et al. Intravitreal polymeric nanocarriers with long ocular retention and targeted delivery to the retina and optic nerve head region. Pharmaceutics. 2021; 13 (4): 445
CN102083411B (zh) 载体
CN119192407B (zh) 一种多肽-地塞米松偶联物及其制备方法与应用
ES2991634T3 (es) Vasodilatadores para su uso en el tratamiento de un trastorno isquémico de la retina
JP2021522215A (ja) 蛍光マーカーの鼻腔内送達
Chaw Fundamental study of nanoliposomes for ocular therapy
CN115869416A (zh) 用于眼部靶向递药的细胞膜、药物载体、组合物及其制备方法和用途
US20220096633A1 (en) Long-acting photoreceptor-binding nanoparticles, and compositions and methods thereof
US20080147039A1 (en) Vitreous body visualization agent

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190618

FZDE Discontinued

Effective date: 20210203